Latest News - Abbott Laboratories
Top Corporates Hub
Abbott Laboratories
AbbVie’s (NYSE:ABBV) Q2: Beats On Revenue
31.07.2025 12:10
Pharmaceutical company AbbVie (NYSE:ABBV) announced better-than-expected revenue in Q2 CY2025, with sales up 6.6% year on year to $15.42 billion. Its non-GAAP profit of $2.97 per share was 2.1% above analysts’ consensus estimates.
Estimating The Fair Value Of Abbott Laboratories (NYSE:ABT)
31.07.2025 11:00
Key Insights Abbott Laboratories' estimated fair value is US$133 based on 2 Stage Free Cash Flow to Equity With US$129...
UBS Shrugs Abbott Laboratories’ (ABT) Diagnostic Weakness Affirms ‘Buy’ Rating
31.07.2025 04:23
Abbott Laboratories (NYSE:ABT) is one of the defensive stocks that billionaires are buying amid US trade tariff uncertainty. On July 21, UBS reiterated a ‘Buy’ rating and a $148 price target on the stock. The bullish stance comes on the heels of the stock coming under pressure following the release of lower fiscal year 2025 […]
Europe Defibrillator Market Forecast and Company Analysis Report 2025-2033 Featuring Medtronic, Philips, Nihon Kohden, Boston Scientific, Stryker, Asahi Kasei, LivaNova, and Abbott
29.07.2025 08:38
The Europe defibrillator market, valued at USD 3.87 billion in 2024, is projected to reach USD 7.23 billion by 2033, with a CAGR of 7.2%. Growth drivers include rising cardiovascular diseases, technological advancements, and government initiatives to expand public defibrillator access. Key segments include implantable and external defibrillators with significant usage in hospitals, public, and home settings. The market faces challenges such as high device costs and regulatory complexities. Leadi
Human Papilloma Virus Testing Market Research Report 2025-2033 Featuring Abbott Laboratories, BioMerieux, Bio-Rad Laboratories, Epigenomics, Siemens Healthineers, Hologic, Qiagen, F. Hoffmann-La Roche
29.07.2025 08:02
The Human Papillomavirus (HPV) Testing Market is projected to grow from USD 1.52 billion in 2024 to USD 3.62 billion by 2033, at a 10.11% CAGR from 2025. This growth is fueled by increased cervical cancer awareness, robust screening programs, and advancements in diagnostic technologies. HPV, a significant sexually transmitted infection, plays a critical role in cervical and other cancers, highlighting the importance of early detection through testing. Global initiatives, especially in developed
HCA Beats Q2 Earnings on Higher Admissions, Ups '25 EPS View
25.07.2025 17:11
HCA Healthcare's Q2 earnings rose 24% year over year on stronger patient volumes. EPS for 2025 is expected to be within $25.5-$27, up from the earlier view of $24.05-$25.85.
Venous Thromboembolism Treatment Devices Market Insights, Competitive Landscape, and Forecast Report 2032 Featuring Abbott, Boston Scientific, AngioDynamics, Argon Medical Devices, and Medtronic
25.07.2025 15:13
The Venous Thromboembolism Treatment Devices Market is poised for significant growth, projected to expand at a CAGR of 8.31% from 2025 to 2032. Factors such as rising deep vein thrombosis and pulmonary embolism rates, fueled by aging populations, sedentary lifestyles, and chronic diseases, drive demand. Key market players are innovating with advanced devices, enhancing treatment effectiveness. North America leads the market owing to technological advancements and high disease prevalence. Notable
U.S. Acute External Ventricular Drain Market Analysis Report 2025-2030 Featuring Medtronic, Integra, LifeSciences, Anuncia Medical, Natus, Fuji Systems, B Braun/Aesculap, Boston Scientific, Abbott
25.07.2025 09:27
The U.S. acute external ventricular drain market, valued at USD 86.5 million in 2024, is set to grow at a CAGR of 7.9% from 2025 to 2030. Growth is driven by increased demand for noninvasive neurosurgeries, technological innovations, and rising healthcare spending. Favorable reimbursement policies and an aging population further fuel market expansion. U.S. Acute External Ventricular Drain Market U.S. Acute External Ventricular Drain Market Dublin, July 25, 2025 (GLOBE NEWSWIRE) -- The "U.S. Acut
Institutional owners may ignore Abbott Laboratories' (NYSE:ABT) recent US$10b market cap decline as longer-term profits stay in the green
23.07.2025 11:00
Key Insights Institutions' substantial holdings in Abbott Laboratories implies that they have significant influence...
Abbott Laboratories (ABT): I Am Very Upset With Abbott,” Says Jim Cramer
21.07.2025 12:43
We recently published Jim Cramer Discusses These 10 Stocks & AI-Led Disinflation. Abbott Laboratories (NYSE:ABT) is one of the stocks Jim Cramer recently discussed. Abbott Laboratories (NYSE:ABT) is a healthcare company. While it was one of Cramer’s top stocks for most of this year, this show saw the CNBC TV host take a different tone. […]
Drugs of Abuse (DoA) Testing Market Opportunities and Strategies to 2034 | Strategic Acquisitions Boost Market Position of Leading DOA Testing Companies
21.07.2025 10:13
The global Drugs of Abuse (DOA) testing market is set to grow from $7.29B in 2024 to $16.98B in 2034, driven by healthcare awareness and demand for accurate tests. With North America leading, key growth regions include Asia-Pacific and Eastern Europe. Major players like Abbott are enhancing market strategies with partnerships and innovations, such as mass spectrometry for improved accuracy. Drugs of Abuse (DoA) Testing Market Drugs of Abuse (DoA) Testing Market Dublin, July 21, 2025 (GLOBE NEWSW
Cote d'Ivoire IVD Market Forecast Report 2025-2032 | Opportunities in Public-Private Partnerships, Molecular Diagnostics Demand, Telemedicine and Point-of-Care Testing
21.07.2025 09:22
The Côte d’Ivoire IVD market is poised for growth with the increasing prevalence of infectious diseases, government support, and technological advancements in diagnostics. Key players include Abbott, Roche, and Siemens. The market segments by offerings into reagents, instruments, and services, with reagents poised to dominate due to the high rate of infectious diseases like malaria and HIV. By technology, glucose monitoring is expected to see the highest growth due to rising diabetes awareness.
Kenya IVD Market Research Report 2025-2032 | Opportunities in Increasing Adoption of Self-testing Kits, Emerging Technologies, Shift Towards Personalized Medicine, Integration of Digital Health
21.07.2025 09:20
The Kenya in vitro diagnostics (IVD) market is set for significant growth, driven by a high incidence of infectious diseases like HIV, TB, and malaria, government health initiatives, and increasing demand for quality diagnostics. Key players include Abbott Laboratories, Siemens Healthineers, and Roche. In 2025, the reagents & kits segment is expected to dominate, boosted by the prevalence of infectious and chronic diseases in Kenya. The whole blood glucose monitoring segment is forecasted to exh
How Abbott Laboratories (ABT) Balances Innovation with Shareholder Payouts
19.07.2025 01:14
Abbott Laboratories (NYSE:ABT) is included among the 14 Best Pharma Dividend Stocks to Buy in 2025. Abbott Laboratories (NYSE:ABT) has long held a strong position in the heavily regulated healthcare industry. Over the years, it has earned the trust of both doctors and consumers, making its well-established brands more appealing in the market. In recent […]
Stocks Pressured by Weakness in Netflix and Health Insurers
18.07.2025 15:24
The S&P 500 Index ($SPX ) (SPY ) today down -0.08%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.44%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.15%. September E-mini S&P futures (ESU25 ) are down -0.14%, and September E-mini Nasdaq futures (NQU25...
Abbott Laboratories (ABT) Drops on Lower Full-Year Guidance
18.07.2025 15:01
We recently published These 10 Stocks Just Lost Their Spark. Abbott Laboratories (NYSE:ABT) is one of the worst-performing companies on Thursday. Abbott Laboratories declined by 8.52 percent on Thursday to end at $120.51 apiece as investors were disheartened by the lowering of its full-year guidance. For the full year, Abbott Laboratories (NYSE:ABT) now projects organic […]
Stock Market News for Jul 18, 2025
18.07.2025 13:47
U.S. stocks ended higher on Thursday, with the S&P 500 and the Nasdaq closing at new record highs, as fresh economic data and solid earnings from a slew of big companies bolstered investors' faith in the economy.
Are Medical Stocks Lagging Abbott Laboratories (ABT) This Year?
18.07.2025 13:40
Here is how Abbott (ABT) and Astellas Pharma Inc. (ALPMY) have performed compared to their sector so far this year.
Snowflake initiated, Chipotle upgraded: Wall Street's top analyst calls
18.07.2025 13:38
Snowflake initiated, Chipotle upgraded: Wall Street's top analyst calls
Down 9.0% in 4 Weeks, Here's Why Abbott (ABT) Looks Ripe for a Turnaround
18.07.2025 13:35
Abbott (ABT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.